Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071027 | 0.97 | KMT2A (0.49) | KMT2AMEN1HRH1CES2KDM4C | |
| SCHEMBL20548080 | 0.92 | KMT2A (0.41) | KMT2AMEN1HRH1CYP4F2CYP4A11 | |
| SCHEMBL22325517 | 0.88 | MEN1 (0.48) | KMT2AMEN1 | |
| SCHEMBL1263510 | 0.85 | MEN1 (0.50) | KMT2AMEN1 | |
| SCHEMBL11537124 | 0.85 | MEN1 (0.50) | KMT2AMEN1 | |
| SCHEMBL8003850 | 0.84 | MEN1 (0.48) | KMT2AMEN1 | |
| SCHEMBL374442 | 0.83 | KMT2A (0.44) | KMT2AMEN1 | |
| SCHEMBL7939089 | 0.83 | MEN1 (0.50) | KMT2AMEN1CES2KDM4C | |
| SCHEMBL20547938 | 0.82 | KMT2A (0.41) | KMT2AMEN1KDM4CADORA3 | |
| SCHEMBL20547937 | 0.82 | KMT2A (0.41) | KMT2AMEN1KDM4CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | KMT2A 2404/4885MEN1 474/4885HRH1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.